"Rank","NCT Number","Title","Acronym","Status","Study Results","Conditions","Interventions","Outcome Measures","Sponsor/Collaborators","Gender","Age","Phases","Enrollment","Funded Bys","Study Type","Study Designs","Other IDs","Start Date","Primary Completion Date","Completion Date","First Posted","Results First Posted","Last Update Posted","Locations","Study Documents","URL"
1,"NCT03673332","Elderly Cancer PatIents, Safety and qualiTy of Life Under immunOtheraPies","EPITOP-01","Recruiting","No Results Available","Advanced or Metastatic Melanoma|Advanced or Metastatic NSCLC","Drug: immune-checkpoint inhibitors therapies","Number of participants adverse events as assessed by CTCAE v5.0|European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire (QLQ-C30) and Elderly Cancer Patients module (QLQ - ELD14), combined to compute a total score (between 44 and 128 points)|geriatric data modifications under treatment|compare patients and clinician symptoms reporting|Progression-free survival|Overall Survival|correlation between toxicity and efficacy|rate of grade 3 to 5 adverse events 18 weeks after treatment initiation","Institut Paoli-Calmettes|Société Francophone d'Onco-Gériatrie","All","70 Years and older   (Older Adult)","Phase 4","300","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EPITOP-01-IPC 2017-049|2018-002092-18","August 9, 2019","August 15, 2021","December 31, 2021","September 17, 2018",,"September 27, 2019","Assistance Publique des Hôpitaux de Marseille, Marseille, Bouches Du Rhône, France|Institut Paoli-Calmettes, Marseille, Bouches-du Rhône, France|Institut BERGONIE, Bordeaux, France|CENTRE Francois Baclesse, Caen, France|Centre Georges François Leclerc, Dijon, France|Institut Du Cancer de Montpellier, Montpellier, France|Institut Curie, Paris, France|Institut De Cancérologie de l'Ouest, Saint-Herblain, France|IUCT-Oncopole Institut Claudius Rigaud, Toulouse, France",,"https://ClinicalTrials.gov/show/NCT03673332"
2,"NCT03333655","Study to Explore the Mechanism of Acquired Immune Escape In Participants With Metastatic Cancer Progressing on CPI Therapy",,"Recruiting","No Results Available","Neoplasms","Procedure: Biopsy","Number of Gene Alterations in at-Progression Biopsy of Patricipants with Acquired Immune Escape","Hoffmann-La Roche","All","18 Years and older   (Adult, Older Adult)","Phase 4","100","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","ML40108","February 16, 2018","June 1, 2021","June 1, 2021","November 7, 2017",,"June 3, 2020","UCSF Comp Canc Ctr, San Francisco, California, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Yale Cancer Center; Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|Washington University School of Medicine; Dept of Medicine/Div of Medical Oncology, Saint Louis, Missouri, United States|Herbert Irving Comprehensive Cancer Center; Herbert Irving Pavillion, New York, New York, United States|Sarah Cannon Cancer Center, Arrington, Tennessee, United States|Centre Leon Berard; Service Oncologie Medicale, Lyon, France|Institut Universitaire du Cancer - Oncopole Toulouse (IUCT-O), Toulouse, France|Seoul National University Hospital; Department of Oncology, Seoul, Korea, Republic of|Asan Medical Center, Uni Ulsan Collegemedicine; Dept.Internal Medicine / Divisionhematology/Oncology, Seoul, Korea, Republic of|Clinica Universitaria de Navarra; Servicio de oncología, Pamplona, Navarra, Spain|Hospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona, Spain|Barts Hospital; Institute of Cancer, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03333655"
3,"NCT03849131","Patient-Reported AutoImmunity Secondary to Cancer immunothErapy","PRAISE","Recruiting","No Results Available","Opportunistic Autoimmune Diseases","Biological: Biological collection","incidence of severe autoimmune manifestations in patients treated with BMS checkpoint inhibitors.|Comparison of the age for the two groups of patients|Comparison of the gender for the two groups of patients|Comparison of the body-mass index for the two groups of patients|Comparison of the types of cancer for the two groups of patients|Comparison of the number of previous lines of chemotherapy for the two groups of patients|Event-free survival of patients|Description of flares or worsening of pre-existing autoimmune diseases|Comparison of baseline predictive factors of autoimmune manifestations for the two groups of patients","University Hospital, Strasbourg, France","All","18 Years and older   (Adult, Older Adult)","Phase 4","2000","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","6994","November 29, 2019","November 2026","November 2026","February 21, 2019",,"January 27, 2020","Hopitaux universitaires de strasbourg, Strasbourg, Alsace, France",,"https://ClinicalTrials.gov/show/NCT03849131"
4,"NCT04036721","Coorticosteroid Regimen in Patients With Anti-PD-1/PD-L1 Induced Pneumonitis","PROS-CONS","Recruiting","No Results Available","Lung Neoplasm Malignant|Interstitial Lung Disease","Drug: Prolonged glucocorticosteroid (prednisone) regimen|Drug: Short glucocorticosteroid (prednisone) regimen","Pneumonitis relapse|Pneumonitis related deaths|Radiological regression of pneumonitis|Overall survival|Progression-free survival|Incidence of treatment related adverse events.","National Institute for Tuberculosis and Lung Diseases, Poland","All","18 Years and older   (Adult, Older Adult)","Phase 4","85","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","KB-57/2019","October 1, 2019","February 1, 2021","February 1, 2022","July 30, 2019",,"February 27, 2020","Instutut Gruzlicy I Chorob Pluc, Warszawa, Mazowieckie, Poland",,"https://ClinicalTrials.gov/show/NCT04036721"
5,"NCT04059887","Evaluation of Blood TMB for the Efficacy of Atezolizumab [BUDDY]","BUDDY","Recruiting","No Results Available","Lung Neoplasm Malignant","Drug: Atezolizumab Injection [Tecentriq]","Objective response rate (ORR)|Progression-free survival (PFS)|Safety profile","Chonnam National University Hospital|Roche Pharma AG","All","18 Years and older   (Adult, Older Adult)","Phase 4","100","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","H2019-0351","December 18, 2019","December 2020","October 2021","August 16, 2019",,"January 14, 2020","Chonnam National University Hwasun Hospital, Jeollanam-do, 전라남도, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT04059887"
